Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 10, 2013, Pages 1328-1335

  Choi, H W ^a   Miele, K ^a   Dowdy, D ^b   Shah, Maunank ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Diagnostics; Genexpert; MTD

Indexed keywords

TUBERCULOSTATIC AGENT;

ALGORITHM; ARTICLE; BACTERIUM CULTURE; CARTRIDGE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; MEDICAL DEVICE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SPUTUM ANALYSIS; SPUTUM CYTODIAGNOSIS; UNITED STATES; XPERT;

ALGORITHMS; BACTERIOLOGICAL TECHNIQUES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; SPUTUM; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 84884639475     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0095     Document Type: Article

References (35)

1. Centers for Disease Control and Prevention. Reported tuberculosis in the United States-2011. Atlanta, GA, USA: CDC, 2012. http://www.cdc.gov/tb/ statistics/reports/2011/pdf/report2011.pdf Accessed July 2013.
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Diagnostic standards and classifi cation of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1376- 1395.
3. Maryland Department of Health & Mental Hygiene. Maryland TB guidelines for prevention and treatment of tuberculosis. Baltimore, MD, USA: DHMH, 2007. http://ideha.dhmh.maryland.gov/OIDPCS/CTBCP/CTBCPDocuments/ tbguidelines.pdf Accessed July 2013.
4. Jensen P A, Lambert L A, Iademarco M F, Ridzon R; US Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care facilities. Morb Mortal Wkly Rep 2005; 54(RR-17): 1-141.
5. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005; 172: 1169-1227.
6. American Thoracic Society. Rapid diagnostic tests for tuberculosis- workshop report. New York, NY, USA: ATS, 1997. http://www.thoracic.org/ statements/resources/mtpi/rapidtb1-12.pdf Accessed July 2013.
7. Centers for Disease Control and Prevention. Update: nucleic acid amplifi cation tests for tuberculosis. MMWR Morb Mortal Wkly Rep 2000; 49: 593-594.
8. Dowdy D W, Maters A, Parrish N, Beyrer C, Dorman S E. Cost-effectiveness analysis of the Gen-Probe Amplifi ed Mycobacterium Tuberculosis Direct test as used routinely on smearpositive respiratory specimens. J Clin Microbiol 2003; 41: 948-953.
9. Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
10. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011; 377: 1495-1505.
11. World Health Organization. Automated real-time nucleic acid amplifi cation technology for rapid and simultaneous detection of tuberculosis and drug resistant tuberculosis: policy statement. WHO/HTM/TB/2011.4. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/ 9789241501545-eng.pdf Accessed July 2013.
12. Foundation for Innovative New Diagnostics. Negotiated prices for Xpert® MTB/RIF and FIND country list. Geneva, Switzerland: FIND, 2013. http://www.finddiagnostics.org/about/what-we-do/successes/find-negotiated- prices/xpert-mtb-rif.htmlAccessedJuly2013.
13. Cepheid. Pricing to the FIND target market of 145 countries. Sunnyvale, CA, USA: Cepheid, 2012. http://www.cepheidcares.com/tb/cepheid-vision.html Accessed July 2013.
14. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high-burden countries: A cost-effectiveness analysis. PLoS Med 2012; 8: e1001120.
15. Brown R E, Miller B, Taylor W R, et al. Health care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595-1600.
16. de Perio M A, Tsevat J, Roselle G A, Kralovic S M, Eckman M H. Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch Intern Med 2009; 169: 179-187.
17. Agency for Healthcare Research and Quality. Medical Expenditure Panel survey. Rockville, MD, USA: AHRQ, 2009. http://meps.ahrq.gov/mepsweb/data-stats/ summ-tables/hc/mean-expend/2009/table2.htm Accessed July 2013.
18. Kaiser Family Foundation. Hospital in-patient expenses. Menlo Park, CA, USA: KFF, 2012. http://www.statehealthfacts.org/comparemaptable.jsp?ind= 273&cat=5 Accessed August 2012.
19. Rajbhandary S S, Marks S M, Bock N N. Costs of patients hospitalized for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2004; 8: 1012-1016.
20. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184.
21. Rimland D, Navin T R, Lennox J L, et al. Prospective study of etiologic agents of community-acquired pneumonia in patients with HIV infection. AIDS 2002; 16: 85-95.
22. Colice G L, Morley M A, Asche C, Birnbaum H G. Treatment costs of community-acquired pneumonia in an employed population. Chest 2004; 125: 2140-2145.
23. Tiemersma E W, van der Werf M J, Borgdorff M W, Williams B G, Nagelkerke N J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS ONE 2011; 6: e17601.
24. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
25. Centers for Disease Control and Prevention/American Thoracic Society. Diagnostic standards and classifi cation of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395.
26. Steingart K R, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: A systematic review. Lancet Infect Dis 2006; 6: 664-674.
27. Guerra R L, Hooper N M, Baker J F, et al. Use of the Amplifi ed Mycobacterium Tuberculosis Direct test in a public health laboratory: test performance and impact on clinical care. Chest 2007; 132: 946-951.
28. Guo N, Marra C A, Marra F, Moadebi S, Elwood R K, Fitzgerald J M. Health state utilities in latent and active tuberculosis. Value Health 2008; 11: 1154-1161.
29. Sohn H, Minion J, Albert H, Dheda K, Pai M. TB diagnostic tests: how do we figure out their costs? Expert Rev Anti Infect Ther 2009; 7: 723-733.
30. Shah M, Miele K, Choi H, et al. QuantiFERON-TB Gold In- Tube implementation for latent tuberculosis diagnosis in a public health clinic: A cost-effectiveness analysis. BMC Infect Dis 2012; 12: 360.
31. Hirth R A, Chernew M E, Miller E, Fendrick A M, Weissert W G. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-342.
32. Owens D K. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-717.
33. World Health Organization. Implementation and roll-out of Xpert MTB/RIF. May 2012 update. Geneva, Switzerland: WHO, 2012. http://www.stoptb.org/wg/gli/ assets/documents/Xpert%20MTB-RIF%20UPDATE%20May%202012.pdf Accessed July 2013.
34. Schnippel K, Meyer-Rath G, Long L, et al. Scaling up Xpert MTB/RIF technology: the costs of laboratory- vs. clinic-based roll-out in South Africa. Trop Med Int Health 2012; 17: 1142- 1151.
35. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLoS ONE 2012; 7: e36966.